{"id":"atherosclerosis-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Mild systemic inflammation"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The atherosclerosis vaccine works by training the adaptive immune system to target pathogenic antigens associated with atherosclerotic lesions, particularly oxidized low-density lipoprotein (oxLDL) and related epitopes. By promoting a therapeutic immune response against these disease-associated antigens, the vaccine aims to reduce plaque progression, stabilize existing lesions, and lower cardiovascular event risk in patients with established atherosclerotic disease.","oneSentence":"An immunotherapeutic vaccine that stimulates the immune system to recognize and attack oxidized lipoproteins and atherosclerotic plaques.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:15.247Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atherosclerosis (cardiovascular disease prevention and progression reduction)"}]},"trialDetails":[{"nctId":"NCT06508437","phase":"PHASE4","title":"Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2024-10-21","conditions":"Coronary Artery Disease, Inflammatory Response, Atherosclerosis","enrollment":47},{"nctId":"NCT03042741","phase":"PHASE3","title":"Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity","status":"UNKNOWN","sponsor":"Immunitor LLC","startDate":"2017-02-01","conditions":"Atherosclerosis","enrollment":300},{"nctId":"NCT00664339","phase":"PHASE4","title":"Flu Vaccination in Congestive Heart Failure","status":"COMPLETED","sponsor":"La Fundacion Favaloro para la Investigacion y la Docencia Medica","startDate":"2007-05","conditions":"Heart Failure","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"atherosclerosis vaccine","genericName":"atherosclerosis vaccine","companyName":"Immunitor LLC","companyId":"immunitor-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"An immunotherapeutic vaccine that stimulates the immune system to recognize and attack oxidized lipoproteins and atherosclerotic plaques. Used for Atherosclerosis (cardiovascular disease prevention and progression reduction).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}